Cardinal Health, Inc. (FRA:CLH)
Germany · Delayed Price · Currency is EUR | Market Cap | 45.71B +53.3% |
| Revenue (ttm) | 222.54B +14.2% |
| Net Income | 1.50B +9.8% |
| EPS | 6.33 +12.1% |
| Shares Out | n/a |
| PE Ratio | 30.47 |
| Forward PE | 17.91 |
| Dividend | 1.77 (0.90%) |
| Ex-Dividend Date | Oct 1, 2026 |
| Volume | n/a |
| Open | 196.45 |
| Previous Close | 202.10 |
| Day's Range | 196.45 - 196.45 |
| 52-Week Range | 124.60 - 213.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 30, 2026 |
About Cardinal Health
Cardinal Health, Inc. operates as a healthcare services and products company in the United States and internationally. It operates in two segments: Pharmaceutical and Specialty Solutions, and Global Medical Products and Distribution. The company offers customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. It distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. T... [Read more]
Financial Performance
In fiscal year 2026, Cardinal Health's revenue was $254.25 billion, an increase of 14.23% compared to the previous year's $222.58 billion. Earnings were $1.71 billion, an increase of 9.80%.
Financial numbers in USD Financial StatementsNews
Cardinal Health Transcript: 2026 Global Healthcare Conference
All five segments delivered strong double-digit earnings growth, with specialty and pharma outperforming expectations. Strategic acquisitions and operational improvements are driving sustainable growth, while contract structures and a stable customer base support consistency. Cash flow targets are nearly achieved, and at-home solutions are focused on scalable, automated delivery.
Cardinal Health Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Fiscal 2027 guidance projects 13%-15% EPS growth, driven by strong performance across all segments and continued investment in specialty, pharma, and at-home solutions. Strategic customer relationships, diversified revenue streams, and proactive policy management support long-term growth and resilience.
Cardinal Health Transcript: Wells Fargo 21st Annual Healthcare Conference
Strong FY 2026 results were driven by specialty and generics, with FY 2027 guidance above long-term targets. Growth is supported by acquisitions, robust specialty and nuclear businesses, and disciplined capital allocation, while AI and cost optimization remain key priorities.
Cardinal Health initiated with an Outperform at RBC Capital
RBC Capital initiated coverage of Cardinal Health (CAH) with an Outperform rating and $276 price target The firm views the vertical integration of the company’s “higher-growth and higher-margin” servi...
Cardinal Health price target raised to $274 from $251 at Baird
Baird analyst Eric Coldwell raised the firm’s price target on Cardinal Health (CAH) to $274 from $251 and keeps an Outperform rating on the shares.
Cardinal Health price target raised to $280 from $265 at Citi
Citi raised the firm’s price target on Cardinal Health (CAH) to $280 from $265 and keeps a Buy rating on the shares. The firm views the company’s fiscal Q4 report…
Cardinal Health price target raised to $277 from $245 at Wells Fargo
Wells Fargo analyst Stephen Baxter raised the firm’s price target on Cardinal Health (CAH) to $277 from $245 and keeps an Overweight rating on the shares. The firm is raising…
Cardinal Health price target raised to $250 from $240 at Mizuho
Mizuho raised the firm’s price target on Cardinal Health (CAH) to $250 from $240 and keeps an Outperform rating on the shares. The firm says management reinforced its positive preview…
Cardinal Health price target raised to $280 from $274 at UBS
UBS raised the firm’s price target on Cardinal Health (CAH) to $280 from $274 and keeps a Buy rating on the shares. Momentum is continuing into FY27, but the focus…
Cardinal Health price target raised to $270 from $265 at Evercore ISI
Evercore ISI raised the firm’s price target on Cardinal Health (CAH) to $270 from $265 and keeps an Outperform rating on the shares.
Cardinal Health price target raised to $265 from $255 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Cardinal Health (CAH) to $265 from $255 and keeps an Overweight rating on the shares.
Cardinal Health price target raised to $275 from $258 at Barclays
Barclays raised the firm’s price target on Cardinal Health (CAH) to $275 from $258 and keeps an Overweight rating on the shares. The firm says Cardinal Health offered a “reasonably…
Cardinal Health price target raised to $260 from $215 at JPMorgan
JPMorgan analyst Lisa Gill raised the firm’s price target on Cardinal Health (CAH) to $260 from $215 and keeps a Neutral rating on the shares post the fiscal Q4 earnings…
Cardinal Health price target raised to $280 from $275 at TD Cowen
TD Cowen analyst Charles Rhyee raised the firm’s price target on Cardinal Health (CAH) to $280 from $275 and keeps a Buy rating on the shares. The firm said they…
Cardinal Health price target raised to $292 from $275 at Leerink
Leerink raised the firm’s price target on Cardinal Health (CAH) to $292 from $275 and keeps an Outperform rating on the shares.
Cardinal Health Earnings Call Transcript: Q4 2026
Q4 and fiscal 2026 saw strong revenue, profit, and cash flow growth, led by Pharmaceutical and Specialty Solutions and other growth businesses. Fiscal 2027 guidance calls for double-digit EPS and profit growth, continued investment, and robust capital returns, with risks from tariffs, input costs, and regulatory changes.
Cardinal Health Earnings release: Q4 2026
Cardinal Health released its Q4 2026 earnings on August 11, 2026, summarizing the period's financial results.
Cardinal Health Slides: Q4 2026
Cardinal Health has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on August 11, 2026.
Cardinal Health Annual report: Q4 2026
Cardinal Health has published its Q4 2026 annual report on August 11, 2026.
Cardinal Health forecasts full-year profit above estimates on specialty drug strength
U.S. drug distributor Cardinal Health on Tuesday forecast fiscal 2027 profit well above Wall Street expectations after topping fourth-quarter profit estimates, driven by sustained demand for special...
Can Cardinal Health's Strong Earnings Guidance Offset a Mixed Quarter?
Cardinal Health reports mixed quarterly performance across its business segments as earnings get a lift from one-time tariff refunds.
Cardinal Health Logs Mixed Sales, Sees Growth in New Year
Cardinal Health had a mixed fiscal fourth quarter in terms of sales across its two main business lines, but expects revenue to rise in both segments in the new fiscal year.
Cardinal Health reports Q4 ex-items EPS $2.60, consensus $2.42
Reports Q4 revenue $63.67B, consensus $65.11B. “Fiscal 2026 was a standout year for Cardinal Health (CAH) and I am pleased with our strong fourth quarter results,” said Jason Hollar, CEO…
Cardinal Health sees FY27 EPS $12.40-$12.60, consensus $12.05
The company said, “Financial guidance for fiscal year 2027 reflects the estimated impact of the Company’s recently completed tuck-in acquisition of Strive Medical and the announced tuck-in acquisition...
Cardinal Health Reports Fourth Quarter and Fiscal Year 2026 Results and Provides Fiscal Year 2027 Guidance
Fourth quarter revenue increased 6% to $63.7 billion Fourth quarter GAAP 1 diluted EPS increased 70% to $1.70 Excluding a one-time positive impact of $0.31 from the recognition of the IEEPA tariff ref...